Funding
← Back to your selection

Mubadala Capital

Activity from announced rounds

Activity in this selectionUnited States

Mubadala Capital is the investment manager whose official portfolio includes Ollin, Alloy, Juvena and Crusoe.

Recorded funding activity

Ollin develops retinal-disease antibodies. Alloy supplies discovery platforms and services, while Crusoe develops computing infrastructure. The manager remains separate from Mubadala Investment Company; the Precision Neuroscience relation stays in draft.

Sources
Rounds participated in
6
Confirmed lead rounds
1
3 roles undisclosed
New companies
6
First participation on record · 0 follow-on
Funding in participating rounds
$20.6B
6 disclosed · full round size, not this investor’s share

By stage

Series C+3
Series B2
Undisclosed1

By primary sector

Biotech3
AI1
Healthtech1
Mobility1

By country

United States6

Rounds

6 in this selection
Precision Neuroscience

Develops a brain-computer interface intended to help people with paralysis operate digital devices.

$250MSeries D
Participant
Crusoe

AI infrastructure combining GPU cloud services, managed AI tools, large-scale data centers and modular AI factories for model developers and enterprises.

$3.9BSeries F (initial close; anticipated total)
Lead
Ollin Biosciences

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B
Role not disclosed
Alloy Therapeutics

Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners.

$40MSeries E
Role not disclosed
Waymo

Waymo develops autonomous driving technology and operates a fully driverless ride-hailing service.

$16BInvestment round
Participant